


Serial No.: 10/509,584
Case No.: 21085
Page No.: 2
RECEIVED
CENTRAL FAX CENTER

IN THE CLAIMS

SEP 27 2007

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A compound of structural formula I:



(I)

or a pharmaceutically acceptable salt thereof, wherein;

R¹ is selected from:

- (1) C₁₋₁₀alkyl,
- (2) C₃₋₁₀cycloalkyl,
- (3) cycloheteroalkyl,
- (4) aryl, and
- (5) heteroaryl,

wherein ~~any~~ alkyl is optionally substituted with one, two, three or four substituents independently selected from R^a, and each cycloalkyl, cycloheteroalkyl, aryl and heteroaryl are optionally substituted with one, two, three or four substituents independently selected from R^b;

R² is selected from:

- (1) C₃₋₁₀cycloalkyl,
- (2) cycloheteroalkyl,
- (3) aryl,
- (4) heteroaryl,
- (5) -OR^d,
- (6) -NR^cR^d, and
- (7) -CO₂R^d,

wherein each alkyl is optionally substituted with one, two, three or four substituents independently selected from R^a, and each cycloalkyl, and cycloheteroalkyl aryl and heteroaryl are optionally substituted with one, two, three or four substituents independently selected from R^b;

R³ is selected from:

Serial No.: 10/509,584
Case No.: 21085Y
Page No.: 3

- (1) C₁₋₄alkyl,
- (2) C₂₋₄alkenyl,
- (3) C₂₋₄alkynyl,
- (4) C₃₋₇cycloalkyl,

wherein alkyl, alkenyl, alkynyl, and cycloalkyl are optionally substituted with one, two, three or four substituents independently selected from R^a;

R⁴ is selected from:

- (1) hydrogen,
- (2) C₁₋₄alkyl,
- (3) C₂₋₄alkenyl,
- (4) C₂₋₄alkynyl,
- (5) -OR^c,
- (6) -CO₂R^c
- (7) -OCOR^c
- (8) -OCOOR^c
- (9) -OCONR^dR^e
- (10) -NR^dR^e,
- (11) -NH(CO)OR^c,
- (12) -NR^cSO₂R^c
- (13) -S(O)_mR^c
- (14) aryl,
- (15) heteroaryl,

wherein alkyl, alkenyl, alkynyl, cycloalkyl, and cycloheteroalkyl are optionally substituted with one, two, three or four substituents independently selected from R^a, and aryl and heteroaryl are optionally substituted with one, two, three or four substituents independently selected from R^b;

R⁶ is selected from:

- (1) hydrogen,
- (2) C₁₋₄alkyl,
- (3) C₂₋₄alkenyl,
- (4) C₂₋₄alkynyl,
- (5) -OR^d,
- (6) halogen,
- (7) -CN,
- (8) -NR^cR^d,

Serial No.: 10/509,584
Case No.: 21085Y
Page No.: 4

wherein alkyl, alkenyl, and alkynyl are optionally substituted with one to four substituents independently selected from R^a

A is benzodioxane or dihydrobenzodioxane, a 3- to 8 membered monocyclic saturated ring incorporating the same carbon atom to which R^4 is attached and optionally containing one to two heteroatoms chosen from oxygen, nitrogen, and sulfur, and to which an aryl or heteroaryl ring is fused, wherein said bicyclic ring is optionally fused to another aryl or heteroaryl ring to form a tricyclic ring wherein the A ring system is optionally substituted with one, two, three or four substituents selected from a group independently selected from oxo and R^b ;

each R^a is independently selected from:

- (1) $-OR^d$,
- (2) $-NR^cS(O)_mR^d$,
- (3) $-NO_2$,
- (4) halogen,
- (5) $-S(O)_mR^c$,
- (6) $-SR^c$,
- (7) $-S(O)_2OR^c$,
- (8) $-S(O)_mNR^cR^d$,
- (9) $-NR^cR^d$,
- (10) $-O(CR^cR^f)_nNR^cR^d$,
- (11) $-C(O)R^c$,
- (12) $-CO_2R^c$,
- (13) $-CO_2(CR^cR^f)_nCONR^cR^d$,
- (14) $-OC(O)R^c$,
- (15) $-CN$,
- (16) $-C(O)NR^cR^d$,
- (17) $-NR^cC(O)R^d$,
- (18) $-OC(O)NR^cR^d$,
- (19) $-NR^cC(O)OR^d$,
- (20) $-NR^cC(O)NR^cR^d$,
- (21) $-CR^c(N-OR^d)$,
- (22) CF_3 ,
- (23) $-OCF_3$,
- (24) C_3 -8cycloalkyl, and
- (25) cycloheteroalkyl;

Serial No.: 10/509,584
Case No.: 21085Y
Page No.: 5

each R^b is independently selected from:

- (1) R^a ,
- (2) C_{1-10} alkyl,
- (3) aryl,
- (4) aryl- C_{1-4} alkyl,
- (5) heteroaryl, and
- (6) heteroaryl- C_{1-4} alkyl;

R^c and R^d are independently selected from:

- (1) hydrogen,
- (2) C_{1-10} alkyl,
- (3) C_{2-10} alkenyl,
- (4) C_{2-10} alkynyl,
- (5) cycloalkyl,
- (6) cycloalkyl- C_{1-10} alkyl;
- (7) cycloheteroalkyl,
- (8) cycloheteroalkyl- C_{1-10} alkyl;
- (9) aryl,
- (10) heteroaryl,
- (11) aryl- C_{1-10} alkyl, and
- (12) heteroaryl- C_{1-10} alkyl, or

R^c and R^d together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0, 1, or 2 additional heteroatoms independently selected from oxygen, sulfur and N- R_g ,

each R^c and R^d may be unsubstituted or substituted on a carbon or nitrogen atom with one, two or three substituents selected from R_h ;

R^e and R^f are independently selected from hydrogen, C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, cycloalkyl, cycloalkyl- C_{1-10} alkyl, cycloheteroalkyl, cycloheteroalkyl- C_{1-10} alkyl, aryl, heteroaryl, aryl- C_{1-10} alkyl, and heteroaryl- C_{1-10} alkyl; or

R^e and R^f together with the carbon to which they are attached form a ring of 5 to 7 members containing 0, 1, or 2 heteroatoms independently selected from oxygen, sulfur and nitrogen;

each R_g is independently selected from

- (1) hydrogen,
- (2) C_{1-10} alkyl,
- (3) C_{3-8} cycloalkyl,

Serial No.: 10/509,584
Case No.: 21085Y
Page No.: 6

- (4) heterocycloalkyl,
- (5) aryl,
- (6) arylC₁₋₄alkyl,
- (7) heteroaryl,
- (8) heteroarylC₁₋₄alkyl,
- (9) -S(O)_mR^c,
- (10) -C(O)R^c,
- (11) -CO₂R^c,
- (12) -CO₂(CR^eR^f)_nCONR^cR^d, and
- (13) -C(O)NR^cR^d;

each R^h is independently selected from:

- (1) halogen,
- (2) C₁₋₁₀alkyl,
- (3) C₃₋₈cycloalkyl,
- (4) heterocycloalkyl,
- (5) aryl,
- (6) arylC₁₋₄alkyl,
- (7) heteroaryl,
- (8) heteroarylC₁₋₄alkyl,
- (9) -OR^c,
- (10) -NR^cS(O)_mR^d,
- (11) -S(O)_mR^c,
- (12) -SR^c,
- (13) -S(O)₂OR^c,
- (14) -S(O)_mNR^cR^d,
- (15) -NR^cR^d,
- (16) -O(CR^eR^f)_nNR^cR^d,
- (17) -C(O)R^c,
- (18) -CO₂R^c,
- (19) -CO₂(CR^eR^f)_nCONR^cR^d,
- (20) -OC(O)R^c,
- (21) -CN,
- (22) -C(O)NR^cR^d,
- (23) -NR^cC(O)R^d,

Serial No.: 10/509,584
Case No.: 21085Y
Page No.: 7

- (24) $-\text{OC}(\text{O})\text{NR}^c\text{R}^d$,
- (25) $-\text{NR}^c\text{C}(\text{O})\text{OR}^d$,
- (26) $-\text{NR}^c\text{C}(\text{O})\text{NR}^c\text{R}^d$,
- (27) CF_3 , and
- (28) $-\text{OCF}_3$;

wherein aryl is selected from: phenyl, naphthyl, indanyl, indenyl, tetrahydronaphthyl, 2,3-dihydrobenzofuranyl, dihydrobenzopyranyl, and 1,4-benzodioxanyl;

wherein cycloalkyl is selected from: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, tetrahydronaphthyl, decahydronaphthyl, and indanyl;

wherein cycloheteroalkyl is selected from: pyrrolidinyl, piperidinyl, piperazinyl, imidazolidinyl, pyranyl, tetrahydrofuranlyl, 2,3-dihydrofuro(2,3-b)pyridyl, benzoxazinyl, tetrahydrohydroquinolinyl, morpholinyl, dioxanyl, oxanyl, tetrahydroisoquinolinyl, dihydroindolyl, dihydroisoindolyl, perhydroazepinyl, 2-pyridine, 4-pyridone, N-substituted-(1H, 3H)-pyrimidine-2,4-diones, and N-substituted uracils;

wherein heteroaryl is selected from: pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, pyridyl, oxazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, triazinyl, thienyl, pyrimidyl, pyridazinyl, pyrazinyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzofuranlyl, benzothiophenyl, benzotriazolyl, furo(2,3-b)pyridyl, quinolyl, indolyl, isoquinolyl, and oxazolidinyl;

m is selected from 1 and 2; and

n is selected from 1, 2, and 3;

or a pharmaceutically acceptable salt thereof.

2. (original) The compound according to Claim 1, wherein R^4 is selected from:

- (1) hydrogen,
- (2) C_{1-4} alkyl, and
- (3) cyclopropyl,

wherein alkyl and cyclopropyl are optionally substituted with one, two or three R^a substituents; and pharmaceutically acceptable salts thereof.

3. (original) The compound according to Claim 2, wherein R^3 is selected from:

- (1) methyl,
- (2) trifluoromethyl, and
- (3) cyclopropyl;

and pharmaceutically acceptable salts thereof.

Serial No.: 10/509,584
Case No.: 21085Y
Page No.: 8

4. (original) The compound according to Claim 3, R¹ is selected from:

- (1) C₁₋₄alkyl,
- (2) C₃₋₁₀cycloalkyl-,
- (3) cycloheteroalkyl,
- (4) phenyl, and
- (5) pyridyl,

wherein each alkyl is optionally substituted with one R^a substituent, and each cycloalkyl, cycloheteroalkyl, aryl and heteroaryl is optionally substituted with one to three substituents independently selected from R^b;

and pharmaceutically acceptable salts thereof.

5. (original) The compound according to Claim 4, wherein R² is selected from:

R² is selected from:

- (1) C₁₋₁₀alkyl,
- (2) C₃₋₁₀cycloalkyl,
- (3) cycloheteroalkyl,
- (4) aryl,
- (5) heteroaryl,
- (6) -OR^d,
- (7) -NR^cR^d, and
- (8) -CO₂R^d, and

wherein each alkyl is optionally substituted with one, two or three substituents independently selected from R^a, and each cycloalkyl, cycloheteroalkyl, aryl and heteroaryl is optionally substituted with one, two or three substituents independently selected from R^b;

and pharmaceutically acceptable salts thereof.

6. (canceled)

7. (currently amended) The compound according to Claim 1, wherein:
R¹ is selected from:

- (1) isopropyl,
- (2) isobutyl,
- (3) n-propyl,
- (4) cyclopropyl,

Serial No.: 10/509,584
Case No.: 21085Y
Page No.: 9

- (4) cyclopropyl,
- (5) cyclobutyl,
- (6) cyclopentyl,
- (7) cyclohexyl,
- (8) piperidinyl,
- (9) phenyl, and
- (10) pyridyl,

wherein each alkyl is optionally substituted with one R^a substituent, and each cycloalkyl, cycloheteroalkyl, aryl and heteroaryl is optionally substituted with one to three substituents independently selected from R^b ;

R^2 is selected from:

- (1) cyclobutyl,
- (2) cyclopentyl,
- (3) cyclohexyl,
- (4) pyrrolidinyl,
- (5) pyrimidinyl,
- (6) benzoxazolyl,
- (7) dihydroindolyl,
- (8) dihydroquinolinyl,
- (9) benzotriazolyl,
- (10) thiophenyl,
- (11) indolyl,
- (12) indazolyl,
- (13) pyrrolidinyl,
- (14) pyridazinyl,
- (15) triazolyl,
- (16) azaindolyl,
- (17) cyclobutylmethoxy,
- (18) phenyl,
- (19) pyridyl,
- (20) $-NR^cR^d$, and
- (21) $-CO_2R^d$,

wherein each alkyl is optionally substituted with one or two R^a substituents and each phenyl or pyridyl is independently with one to three R^b substituents.

R^3 is methyl;

Serial No.: 10/509,584
Case No.: 21085Y
Page No.: 10

R⁴ is selected from hydrogen and methyl;

R⁶ is selected from:

- (1) hydrogen,
- (2) methyl,
- (3) hydroxyl,
- (4) halogen, and
- (5) -CN;

A is selected from:

- (1) benzodioxanyl, and
- (2) dihydrobenzodioxanyl,
- (3) ~~indanyl,~~
- (4) ~~1,2,3,4 tetrahydronaphthyl,~~
- (5) ~~6,7,8,9 tetrahydro[a][7]annulenyl,~~
- (6) ~~chromanyl,~~
- (7) ~~2,3 dihydrobenzyl furanyl,~~
- (8) ~~1,2,3,4 tetrahydroquinoliny,~~
- (9) ~~1,2,3,4 tetrahydroisoquinoliny,~~
- (10) ~~1,2,3,4 tetrahydro 1,4 quinazoliny,~~ and
- (11) ~~1,2,3,4 tetrahydrocarboliny,~~

each optionally substituted with one, two, or three groups independently selected from R^b;


each R^b is independently selected from:

- (1) methoxy,
- (2) halogen,
- (3) -SH,
- (4) -SCH₃,
- (5) -NH₂,
- (6) -C(O)CH₃,
- (7) -CO₂H,
- (8) -CO₂CH₃,
- (9) -CF₃,
- (10) -OCF₃,
- (11) C₃₋₆ cycloalkyl,
- (12) C₁₋₄ alkyl,
- (13) phenyl,

Serial No.: 10/509,584
Case No.: 21085Y
Page No.: 11

(14) benzyl, and
(15) heteroaryl;
and pharmaceutically acceptable salts thereof.

8. (currently amended) A compound of structural formula IA:



(IA)

or a pharmaceutically acceptable salt thereof, wherein;

R¹ is selected from:

- (1) aryl,
- (2) heteroaryl,

wherein aryl and heteroaryl are optionally substituted with one, two, three or four substituents independently selected from R^b;

R² is selected from:

- (1) aryl,
- (2) heteroaryl,

wherein aryl and heteroaryl are optionally substituted with one, two, three or four substituents independently selected from R^b;

R³ is selected from:

- (1) C₁₋₄alkyl,
- (2) C₂₋₄alkenyl,
- (3) C₂₋₄alkynyl,
- (4) C₃₋₇cycloalkyl,

wherein alkyl, alkenyl, alkynyl, and cycloalkyl are optionally substituted with one, two, three or four substituents independently selected from R^a;

R⁴ is selected from:

- (1) hydrogen,
- (2) C₁₋₄alkyl,
- (3) C₂₋₄alkenyl,
- (4) C₂₋₄alkynyl,

Serial No.: 10/509,584
 Case No.: 21085Y
 Page No.: 12

- (5) $-\text{OR}^c$,
- (6) $-\text{CO}_2\text{R}^c$
- (7) $-\text{OCOR}^c$
- (8) $-\text{OCOOR}^c$
- (9) $-\text{CONR}^d\text{R}^e$
- (10) $-\text{NR}^d\text{R}^e$,
- (11) $-\text{NH}(\text{CO})\text{OR}^c$,
- (12) $-\text{NR}^c\text{SO}_2\text{R}^c$
- (13) $-\text{S}(\text{O})_m\text{R}^c$
- (14) aryl,
- (15) heteroaryl,

wherein alkyl, alkenyl, alkynyl, cycloalkyl, and cycloheteroalkyl are optionally substituted with one, two, three or four substituents independently selected from R^a , and aryl and heteroaryl are optionally substituted with one, two, three or four substituents independently selected from R^b ;

~~A is benzodioxane or dihydrobenzodioxane, a 3 to 8 membered monocyclic saturated ring incorporating the same carbon atom to which R^4 is attached and optionally containing one to two heteroatoms chosen from oxygen, nitrogen, and sulfur, and to which an aryl or heteroaryl ring is fused, wherein said bicyclic ring is optionally fused to another aryl or heteroaryl ring to form a tricyclic ring wherein the A ring system is optionally substituted with one, two, three or four substituents selected from a group independently selected from oxo and R^b ;~~

each R^a is independently selected from:

- (1) $-\text{OR}^d$,
- (2) $-\text{NR}^c\text{S}(\text{O})_m\text{R}^d$,
- (3) $-\text{NO}_2$,
- (4) halogen,
- (5) $-\text{S}(\text{O})_m\text{R}^c$,
- (6) $-\text{SR}^c$,
- (7) $-\text{S}(\text{O})_2\text{OR}^c$,
- (8) $-\text{S}(\text{O})_m\text{NR}^c\text{R}^d$,
- (9) $-\text{NR}^c\text{R}^d$,
- (10) $-\text{O}(\text{CR}^e\text{R}^f)_n\text{NR}^c\text{R}^d$,
- (11) $-\text{C}(\text{O})\text{R}^c$,
- (12) $-\text{CO}_2\text{R}^c$,
- (13) $-\text{CO}_2(\text{CR}^e\text{R}^f)_n\text{CONR}^c\text{R}^d$,

Serial No.: 10/509,584
Case No.: 21085Y
Page No.: 13

- (14) $-\text{OC}(\text{O})\text{R}^{\text{c}}$,
- (15) $-\text{CN}$,
- (16) $-\text{C}(\text{O})\text{NR}^{\text{c}}\text{R}^{\text{d}}$,
- (17) $-\text{NR}^{\text{c}}\text{C}(\text{O})\text{R}^{\text{d}}$,
- (18) $-\text{OC}(\text{O})\text{NR}^{\text{c}}\text{R}^{\text{d}}$,
- (19) $-\text{NR}^{\text{c}}\text{C}(\text{O})\text{OR}^{\text{d}}$,
- (20) $-\text{NR}^{\text{c}}\text{C}(\text{O})\text{NR}^{\text{c}}\text{R}^{\text{d}}$,
- (21) $-\text{CR}^{\text{c}}(\text{N}-\text{OR}^{\text{d}})$,
- (22) CF_3 ,
- (23) $-\text{OCF}_3$,
- (24) $\text{C}_{3-8}\text{cycloalkyl}$, and
- (25) cycloheteroalkyl ;

each R^{b} is independently selected from:

- (1) R^{a} ,
- (2) $\text{C}_{1-10}\text{alkyl}$,
- (3) aryl ,
- (4) $\text{arylC}_{1-4}\text{alkyl}$,
- (5) heteroaryl , and
- (6) $\text{heteroarylC}_{1-4}\text{alkyl}$;

R^{c} and R^{d} are independently selected from:

- (1) hydrogen ,
- (2) $\text{C}_{1-10}\text{alkyl}$,
- (3) $\text{C}_{2-10}\text{alkenyl}$,
- (4) $\text{C}_{2-10}\text{alkynyl}$,
- (5) cycloalkyl ,
- (6) $\text{cycloalkyl-C}_{1-10}\text{alkyl}$;
- (7) cycloheteroalkyl ,
- (8) $\text{cycloheteroalkyl-C}_{1-10}\text{alkyl}$;
- (9) aryl ,
- (10) heteroaryl ,
- (11) $\text{aryl-C}_{1-10}\text{alkyl}$, and
- (12) $\text{heteroaryl-C}_{1-10}\text{alkyl}$, or

Serial No.: 10/509,584
Case No.: 21085Y
Page No.: 14

R^c and R^d together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0, 1, or 2 additional heteroatoms independently selected from oxygen, sulfur and N-
R^g,

each R^c and R^d may be unsubstituted or substituted on a carbon or nitrogen atom with one, two or three substituents selected from R^h;

R^c and R^f are independently selected from hydrogen, C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, cycloalkyl, cycloalkyl-C₁₋₁₀alkyl, cycloheteroalkyl, cycloheteroalkyl-C₁₋₁₀alkyl, aryl, heteroaryl, aryl-C₁₋₁₀alkyl, and heteroaryl-C₁₋₁₀alkyl; or

R^e and R^f together with the carbon to which they are attached form a ring of 5 to 7 members containing 0, 1, or 2 heteroatoms independently selected from oxygen, sulfur and nitrogen;

each R^g is independently selected from

- (1) hydrogen,
- (2) C₁₋₁₀alkyl,
- (3) C₃₋₈cycloalkyl,
- (4) heterocycloalkyl,
- (5) aryl,
- (6) arylC₁₋₄alkyl,
- (7) heteroaryl,
- (8) heteroarylC₁₋₄alkyl,
- (9) -S(O)_mR^c,
- (10) -C(O)R^c,
- (11) -CO₂R^c,
- (12) -CO₂(CR^eR^f)_nCONR^cR^d, and
- (13) -C(O)NR^cR^d;

each R^h is independently selected from:

- (1) halogen,
- (2) C₁₋₁₀alkyl,
- (3) C₃₋₈cycloalkyl,
- (4) heterocycloalkyl,
- (5) aryl,
- (6) arylC₁₋₄alkyl,
- (7) heteroaryl,
- (8) heteroarylC₁₋₄alkyl,
- (9) -OR^c,

Serial No.: 10/509,584
 Case No.: 21085Y
 Page No.: 15

- (10) $-NR^cS(O)_mR^d$,
- (11) $-S(O)_mR^c$,
- (12) $-SR^c$,
- (13) $-S(O)_2OR^c$,
- (14) $-S(O)_mNR^cR^d$,
- (15) $-NR^cR^d$,
- (16) $-O(CR^eR^f)_nNR^cR^d$,
- (17) $-C(O)R^c$,
- (18) $-CO_2R^c$,
- (19) $-CO_2(CR^eR^f)_nCONR^cR^d$,
- (20) $-OC(O)R^c$,
- (21) $-CN$,
- (22) $-C(O)NR^cR^d$,
- (23) $-NR^cC(O)R^d$,
- (24) $-OC(O)NR^cR^d$,
- (25) $-NR^cC(O)OR^d$,
- (26) $-NR^cC(O)NR^cR^d$,
- (27) CF_3 , and
- (28) $-OCF_3$;

wherein aryl is selected from: aryl include phenyl, naphthyl, indanyl, indenyl, tetrahydronaphthyl, 2,3-dihydrobenzo-furanyl, dihydrobenzopyranyl, and 1,4-benzodioxanyl;

wherein cycloalkyl is selected from: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, tetrahydronaphthyl, decahydronaphthyl, and indanyl;

wherein cycloheteroalkyl is selected from: pyrrolidinyl, piperidinyl, piperazinyl, imidazolidinyl, pyranyl, tetrahydrofuranlyl, 2,3-dihydrofuro(2,3-b)pyridyl, benzoxazinyl, tetrahydrohydroquinolinyl, morpholinyl, dioxanyl, oxanyl, tetrahydroisoquinolinyl, dihydroindolyl, dihydroisoindolyl, perhydroazepinyl, 2-pyridine, 4-pyridone, N-substituted-(1H, 3H)-pyrimidine-2,4-diones, and N-substituted uracils;

wherein heteroaryl is selected from: pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, pyridyl, oxazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, triazinyl, thienyl, pyrimidyl, pyridazinyl, pyrazinyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzofuranlyl, benzothiophenyl, benzotriazolyl, furo(2,3-b)pyridyl, quinolyl, indolyl, isoquinolyl, and oxazolidinyl;

m is selected from 1 and 2; and

n is selected from 1, 2, and 3;

or a pharmaceutically acceptable salt thereof.

Serial No.: 10/509,584
Case No.: 21085Y
Page No.: 16

(2) C₁₋₄alkyl, and

(3) cyclopropyl,

wherein alkyl and cyclopropyl are optionally substituted with one, two or three R^a substituents;
and pharmaceutically acceptable salts thereof.

10. (original) The compound according to Claim 9, wherein R³ is selected from:

(1) methyl,

(2) trifluoromethyl, and

(3) cyclopropyl;

and pharmaceutically acceptable salts thereof.

11. (original) The compound according to Claim 10, wherein R¹ is selected from:

(1) phenyl, and

(2) pyridyl;

wherein phenyl and pyridyl are optionally substituted with one or two R^b substituents;
and pharmaceutically acceptable salts thereof.

12. (original) The compound according to Claim 11, wherein R² is selected from:

(1) phenyl, and

(2) pyridyl;

wherein phenyl and pyridyl are optionally substituted with one or two R^b substituents.
and pharmaceutically acceptable salts thereof.

13. (canceled)

14. (currently amended) The compound according to Claim 8, wherein:

R¹ is selected from phenyl and 4-chlorophenyl;

R² is selected from:

(1) phenyl, and

(2) pyridyl,

wherein phenyl and pyridyl are optionally substituted with one or two halogen substituents;
R³ is methyl;

R⁴ is selected from hydrogen and methyl;

A is selected from:

(1) benzodioxanyl, and

Serial No.: 10/509,584
 Case No.: 21085Y
 Page No.: 17

- (2) dihydrobenzodioxanyl,
- ~~(3) indanyl,~~
- ~~(4) 1,2,3,4 tetrahydronaphthyl,~~
- ~~(5) 6,7,8,9 tetrahydro[a][7]annulenyl,~~
- ~~(6) chromanyl,~~
- ~~(7) 2,3 dihydrobenzyl furanyl,~~
- ~~(8) 1,2,3,4 tetrahydroquinoliny,~~
- ~~(9) 1,2,3,4 tetrahydroisoquinoliny,~~
- ~~(10) 1,2,3,4 tetrahydro 1,4 quiazoliny,~~ and
- (11) 1,2,3,4 tetrahydrocarboliny,

each optionally substituted with one, two, or three groups independently selected from R^b;

each R^b is independently selected from:

- (1) methoxy,
- (2) halogen,
- (3) -SH,
- (4) -SCH₃,
- (5) -NH₂,
- (6) -C(O)CH₃,
- (7) -CO₂H,
- (8) -CO₂CH₃,
- (9) -CF₃,
- (10) -OCF₃,
- (11) C₃₋₆ cycloalkyl,
- (12) C₁₋₄ alkyl,
- (13) phenyl,
- (14) benzyl, and
- (15) heteroaryl;

and pharmaceutically acceptable salts thereof.

15. (currently amended) The compound according to Claim 8, selected from:

- (1) *N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,4-benzodioxane-2-carboxamide,
- ~~(2) *N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl) indane-1-carboxamide,~~
- ~~(3) *N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-2,3-dihydrobenzofuran-2-carboxamide,~~
- ~~(4) *N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,2,3,4-tetrahydrocarbazole-1-carboxamide,~~

Serial No.: 10/509,584
Case No.: 21085Y
Page No.: 18

- (2) ~~*N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-indane-1-carboxamide;~~
 (3) ~~*N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-2,3-dihydrobenzofuran-2-carboxamide;~~
 (4) ~~*N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,2,3,4-tetrahydrocarbazole-1-carboxamide;~~
 (5) ~~*N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,2,3,4-tetrahydro-2-naphthamide;~~
 (6) ~~*N*-(3-(4-chlorophenyl)-1-methyl-2-phenylpropyl)-2,3-dihydrobenzofuran-2-carboxamide;~~
 (7) ~~*N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-2-methyl-2,3-dihydrobenzofuran-2-carboxamide;~~
 (8) ~~*N*-(3-(4-chlorophenyl)-1-methyl-2-phenylpropyl)-2-methyl-2,3-dihydrobenzofuran-2-carboxamide;~~
 (9) ~~*N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-2-methyl-1,2,3,4-tetrahydro-2-naphthamide;~~
 (10) ~~*N*-(3-(4-chlorophenyl)-1-methyl-2-phenylpropyl)-2-methyl-1,2,3,4-tetrahydro-2-naphthamide;~~
 (11) ~~*N*-(3-(4-chlorophenyl)-1-methyl-2-phenylpropyl)-1,2,3,4-tetrahydro-2-naphthamide;~~
 (12) ~~*N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-chromane-2-carboxamide;~~
 (13) ~~*N*-(3-(4-chlorophenyl)-1-methyl-2-phenylpropyl)-chromane-2-carboxamide;~~
 (14) ~~*N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-2-methylchromane-2-carboxamide;~~
 (15) ~~*N*-(3-(4-chlorophenyl)-1-methyl-2-phenylpropyl)-2-methylchromane-2-carboxamide;~~
 (16) ~~*N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-chromane-3-carboxamide;~~
 (17) ~~*N*-(3-(4-chlorophenyl)-1-methyl-2-phenylpropyl)-chromane-3-carboxamide;~~
 (18) ~~*N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-3-methylchromane-3-carboxamide;~~
 (19) ~~*N*-(3-(4-chlorophenyl)-1-methyl-2-phenylpropyl)-3-methylchromane-3-carboxamide;~~
 (20) ~~*N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide;~~
 (21) ~~*N*-(3-(4-chlorophenyl)-1-methyl-2-phenylpropyl)-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide;~~
 (22) ~~*N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-2,3-dihydro-1,4-benzodioxane-2-carboxamide;~~
 (23) ~~*N*-(3-(4-chlorophenyl)-1-methyl-2-phenylpropyl)-2,3-dihydro-1,4-benzodioxane-2-carboxamide;~~
 (24) ~~*N*-(3-(4-chlorophenyl)-1-methyl-3-pyridylpropyl)-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide;~~
 (25) ~~*N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-6,7,8,9-tetrahydro-5*H*-benzo[*a*][7]annulene-6-carboxamide;~~
 (26) ~~*N*-(3-(4-chlorophenyl)-1-methyl-2-phenylpropyl)-6,7,8,9-tetrahydro-5*H*-benzo[*a*][7]annulene-6-carboxamide;~~
 (27) ~~*N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-6,7,8,9-tetrahydro-5*H*-benzo[*a*][7]annulene-7-carboxamide;~~
 (28) ~~*N*-(3-(4-chlorophenyl)-1-methyl-2-phenylpropyl)-6,7,8,9-tetrahydro-5*H*-benzo[*a*][7]annulene-7-carboxamide;~~

Serial No.: 10/509,584
 Case No.: 21085Y
 Page No.: 19

- (8) ~~(30)~~ *N*-[3-(4-chlorophenyl)-1-methyl-3-pyridylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide,
 (31) *N*[3-(4-chlorophenyl)-2(S)-phenyl-1(S)-methylpropyl]-3-methylchromane-3-carboxamide,
 (9) ~~(32)~~ *N*-[3-(4-chlorophenyl)-2(S)-phenyl-1(S)-methylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide,
 (10) ~~(33)~~ *N*-[3-(4-chlorophenyl)-2(S)-phenyl-1(S)-methylpropyl]-6-chloro-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide,
 (11) ~~(34)~~ *N*-[3-(4-chlorophenyl)-2(S)-phenyl-1(S)-methylpropyl]-7-chloro-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide;
 and pharmaceutically acceptable salts thereof.

16. (currently amended) The compound according to Claim 8, selected from:

- (1) *N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,4-benzodioxane-2-carboxamide,
~~(2) *N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl) indane-1-carboxamide,~~
~~(3) *N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-2,3-dihydrobenzofuran-2-carboxamide,~~
~~(4) *N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,2,3,4-tetrahydrocarbazole-1-carboxamide,~~
~~(5) *N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,2,3,4-tetrahydro-2-naphthamide, diastereomer I,~~
~~(6) *N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,2,3,4-tetrahydro-2-naphthamide, diastereomer II,~~
~~(7) *N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,2,3,4-tetrahydro-2-naphthamide, diastereomer III,~~
~~(8) *N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,2,3,4-tetrahydro-2-naphthamide, diastereomer IV,~~
~~(9) *N*-(3-(4-chlorophenyl)-1-methyl-2-phenylpropyl)-2,3-dihydrobenzofuran-2-carboxamide~~
~~diastereomer I,~~
~~(10) *N*-(3-(4-chlorophenyl)-1-methyl-2-phenylpropyl)-2,3-dihydrobenzofuran-2-carboxamide~~
~~diastereomer II,~~
~~(11) *N*-(3-(4-chlorophenyl)-1-methyl-2-phenylpropyl)-2,3-dihydrobenzofuran-2-carboxamide,~~
~~diastereomers I and II (1:1),~~
~~(12) *N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-2-methyl-2,3-dihydrobenzofuran-2-carboxamide~~
~~diastereomer I,~~
~~(13) *N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-2-methyl-2,3-dihydrobenzofuran-2-carboxamide~~
~~diastereomer II,~~
~~(14) *N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-2-methyl-2,3-dihydrobenzofuran-2-carboxamide,~~
~~diastereomers I and II (1:1),~~
~~(15) *N*-(3-(4-chlorophenyl)-1-methyl-2-phenylpropyl)-2-methyl-2,3-dihydrobenzofuran-2-carboxamide~~
~~diastereomer I,~~

Serial No.: 10/509,584
Case No.: 21085Y
Page No.: 20

- (15) ~~*N*[3-(4-chlorophenyl)-1-methyl-2-phenylpropyl]-2-methyl-2,3-dihydrobenzofuran-2-carboxamide diastereomer I,~~
- (16) ~~*N*[3-(4-chlorophenyl)-1-methyl-2-phenylpropyl]-2-methyl-2,3-dihydrobenzofuran-2-carboxamide diastereomer II,~~
- (17) ~~*N*[3-(4-chlorophenyl)-1-methyl-2-phenylpropyl]-2-methyl-2,3-dihydrobenzofuran-2-carboxamide, diastereomers I and II (1:1),~~
- (18) ~~*N*[2,3-bis(4-chlorophenyl)-1-methylpropyl]-2-methyl-1,2,3,4-tetrahydro-2-naphthamide diastereomer I,~~
- (19) ~~*N*[2,3-bis(4-chlorophenyl)-1-methylpropyl]-2-methyl-1,2,3,4-tetrahydro-2-naphthamide, diastereomer II,~~
- (20) ~~*N*[3-(4-chlorophenyl)-1-methyl-2-phenylpropyl]-2-methyl-1,2,3,4-tetrahydro-2-naphthamide diastereomers I and II (1:1),~~
- (21) ~~*N*[3-(4-chlorophenyl)-1-methyl-2-phenylpropyl]-1,2,3,4-tetrahydro-2-naphthamide diastereomer I,~~
- (22) ~~*N*[3-(4-chlorophenyl)-1-methyl-2-phenylpropyl]-1,2,3,4-tetrahydro-2-naphthamide diastereomer II,~~
- (23) ~~*N*[3-(4-chlorophenyl)-1-methyl-2-phenylpropyl]-1,2,3,4-tetrahydro-2-naphthamide diastereomers I and II (1:1),~~
- (24) ~~*N*[2,3-bis(4-chlorophenyl)-1-methylpropyl]chromane-2-carboxamide diastereomers I and II (1:1),~~
- (25) ~~*N*[3-(4-chlorophenyl)-1-methyl-2-phenylpropyl]chromane-2-carboxamide diastereomers I and II (1:1),~~
- (26) ~~*N*[2,3-bis(4-chlorophenyl)-1-methylpropyl]-2-methylchromane-2-carboxamide diastereomer I,~~
- (27) ~~*N*[2,3-bis(4-chlorophenyl)-1-methylpropyl]-2-methylchromane-2-carboxamide diastereomer II,~~
- (28) ~~*N*[2,3-bis(4-chlorophenyl)-1-methylpropyl]-2-methylchromane-2-carboxamide diastereomers I and II (1:1),~~
- (29) ~~*N*[3-(4-chlorophenyl)-1-methyl-2-phenylpropyl]-2-methylchromane-2-carboxamide diastereomer I,~~
- (30) ~~*N*[3-(4-chlorophenyl)-1-methyl-2-phenylpropyl]-2-methylchromane-2-carboxamide diastereomer II,~~
- (31) ~~*N*[3-(4-chlorophenyl)-1-methyl-2-phenylpropyl]-2-methylchromane-2-carboxamide diastereomers I and II (1:1),~~
- (32) ~~*N*[2,3-bis(4-chlorophenyl)-1-methylpropyl]chromane-3-carboxamide diastereomers I and II (1:1),~~
- (33) ~~*N*[3-(4-chlorophenyl)-1-methyl-2-phenylpropyl]chromane-3-carboxamide diastereomers I and II (1:1),~~
- (34) ~~*N*[2,3-bis(4-chlorophenyl)-1-methylpropyl]-3-methylchromane-3-carboxamide diastereomers I and II (1:1),~~

Serial No.: 10/509,584
Case No.: 21085Y
Page No.: 21

~~(35) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2-methylchromane-3-carboxamide diastereomers I and II (1:1),~~

(2) (36) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer I,

(3) (37) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer II,

(4) (38) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomers I and II (1:1),

(5) (39) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer I,

(6) (40) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer II,

(7) (41) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomers I and II (1:1),

(8) (42) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-2,3-dihydro-1,4-benzodioxane-2-carboxamide, diastereomer III,

(9) (43) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer IV,

(10) (44) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer I,

(11) (45) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer II,

(12) (46) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomers I and II (1:1),

(13) (47) *N*-[3-(4-chlorophenyl)-1-methy-3-pyridylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomers I and II (3:1),

(14) (48) *N*-[3-(4-chlorophenyl)-1-methy-3-pyridylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomers I and II (1:1),

(15) (49) *N*-[3-(4-chlorophenyl)-1-methy-3-pyridylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer II,

~~(50) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-6,7,8,9-tetrahydro-5*H*-benzo[*a*][7]annulene-6-carboxamide diastereomer I,~~

~~(51) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-6,7,8,9-tetrahydro-5*H*-benzo[*a*][7]annulene-6-carboxamide diastereomer II,~~

Serial No.: 10/509,584
Case No.: 21085Y
Page No.: 22

- (52) ~~*N* [2,3-bis(4-chlorophenyl)-1-methylpropyl]-6,7,8,9-tetrahydro-5*H*-benzo[*a*][7]annulene-6-carboxamide diastereomers I and II (1:1),~~
- (53) ~~*N* [3-(4-chlorophenyl)-1-methyl-2-phenylpropyl]-6,7,8,9-tetrahydro-5*H*-benzo[*a*][7]annulene-6-carboxamide diastereomer I,~~
- (54) ~~*N* [3-(4-chlorophenyl)-1-methyl-2-phenylpropyl]-6,7,8,9-tetrahydro-5*H*-benzo[*a*][7]annulene-6-carboxamide diastereomer II,~~
- (55) ~~*N* [3-(4-chlorophenyl)-1-methyl-2-phenylpropyl]-6,7,8,9-tetrahydro-5*H*-benzo[*a*][7]annulene-6-carboxamide diastereomers I and II (1:1),~~
- (56) ~~*N* [2,3-bis(4-chlorophenyl)-1-methylpropyl]-6,7,8,9-tetrahydro-5*H*-benzo[*a*][7]annulene-7-carboxamide diastereomers I and II (1:1),~~
- (57) ~~*N* [3-(4-chlorophenyl)-1-methyl-2-phenylpropyl]-6,7,8,9-tetrahydro-5*H*-benzo[*a*][7]annulene-7-carboxamide diastereomers I and II (1:1),~~
- (16) (58) *N* [3-(4-chlorophenyl)-1-methyl-2-phenylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer I enantiomer A,
- (17) (59) *N* [3-(4-chlorophenyl)-1-methyl-2-phenylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer I enantiomer B,
- (18) (60) *N* [3-(4-chlorophenyl)-1-methyl-3-pyridylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer I, enantiomer A,
- (19) (61) *N* [3-(4-chlorophenyl)-1-methyl-3-pyridylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer I, enantiomer B,
- (62) ~~*N* [3-(4-chlorophenyl)-2(*S*)-phenyl-1(*S*)-methylpropyl]-3-methylchromane-3-carboxamide diastereomer I,~~
- (63) ~~*N* [3-(4-chlorophenyl)-2(*S*)-phenyl-1(*S*)-methylpropyl]-3-methylchromane-3-carboxamide diastereomer II,~~
- (20) (64) *N* [3-(4-chlorophenyl)-2(*S*)-phenyl-1(*S*)-methylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer I,
- (21) (65) *N* [3-(4-chlorophenyl)-2(*S*)-phenyl-1(*S*)-methylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer II,
- (22) (66) *N* [3-(4-chlorophenyl)-2(*S*)-phenyl-1(*S*)-methylpropyl]-6-chloro-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer I,
- (23) (67) *N* [3-(4-chlorophenyl)-2(*S*)-phenyl-1(*S*)-methylpropyl]-7-chloro-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer I,
- (24) (68) *N* [3-(4-chlorophenyl)-2(*S*)-phenyl-1(*S*)-methylpropyl]-6-chloro-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer II,

Serial No.: 10/509,584
Case No.: 21085Y
Page No.: 23

and pharmaceutically acceptable salts thereof.

17. (canceled)

18. (withdrawn) The method according to Claim 17 wherein the disease mediated by the Cannabinoid-1 receptor is selected from: psychosis, memory deficit, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders, cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, schizophrenia, substance abuse disorders, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, asthma, obesity, and other eating disorders associated with excessive food intake.

19. (withdrawn) The method according to Claim 18 wherein the disease mediated by the Cannabinoid-1 receptor is an eating disorder associated with excessive food intake.

20. (withdrawn) The method according to Claim 19 wherein the eating disorder associated with excessive food intake is selected from obesity, bulimia nervosa, and compulsive eating disorders.

21. (withdrawn) The method according to Claim 20 wherein the eating disorder associated with excessive food intake is obesity.

22. (withdrawn) A method of preventing obesity in a person at risk for obesity comprising administration to said person of about 0.001 mg to about 100 mg per kg of a compound according to Claim 1.

23. (original) A composition comprising a compound according to Claim 1 and a pharmaceutically acceptable carrier.

Claims 24 – 29 (previously canceled)